Labeled for this condition
Medicines for prostate cancer
17 medicines have an FDA label indicated for prostate cancer; 4 are listed from generic labelers and 0 have a presentation in shortage now (FDA files, October 8, 2026).
Which medicines are labeled for prostate cancer?
Each label names the condition in its indications; the record shows the label's words. A list of labeled medicines is not a treatment plan.
| Medicine | Brand names | Generic labelers (all forms) | Pharmacy cost | Boxed warning | Shortage | Recalls since 2012 |
|---|---|---|---|---|---|---|
| Docetaxel | Beizray, Docivyx | 14 labelers | n/a | Yes | A presentation being discontinued | 7 |
| Abiraterone | Zytiga, Yonsa, Abirtega | 23 labelers | $0.774 per tablet 250 mg tablet | No | No current entry | 0 |
| Leuprolide | Lupron, Eligard, Camcevi | 12 labelers | $197.61 per unit 2wk 14 mg/2.8 mL kt | No | No current entry | 6 |
| Talazoparib | Talzenna | none listed | n/a | No | No current entry | 0 |
| Enzalutamide | Xtandi | none listed | n/a | No | No current entry | 0 |
| Olaparib | Lynparza | none listed | n/a | No | No current entry | 0 |
| Triptorelin | Trelstar, Triptodur | none listed | n/a | No | No current entry | 0 |
| Rucaparib camsylate | Rubraca | none listed | n/a | No | No current entry | 0 |
| Abiraterone and niraparib | Akeega | none listed | n/a | No | No current entry | 0 |
| Apalutamide | Erleada | none listed | n/a | No | No current entry | 0 |
| Capivasertib | Truqap | none listed | n/a | No | No current entry | 0 |
| Degarelix | Firmagon | none listed | n/a | No | No current entry | 2 |
| Cabazitaxel | Jevtana | none listed | n/a | Yes | No current entry | 0 |
| Lutetium lu 177 vipivotide tetraxetan | Pluvicto | none listed | n/a | No | No current entry | 0 |
| Nilutamide | none listed | 1 labeler | n/a | Yes | A presentation being discontinued | 0 |
| Radium ra 223 dichloride | Xofigo | none listed | n/a | No | No current entry | 0 |
| Relugolix | Orgovyx | none listed | n/a | No | No current entry | 0 |
Source: FDA drug labels (indications) via openFDA; NDC Directory; CMS NADAC of October 7, 2026; FDA shortages and recalls (FDA files October 8, 2026)
What do pharmacies pay?
Each medicine's most widely listed form, per unit, in the NADAC survey: what pharmacies paid, not what a patient pays; strengths differ, so compare like with like.
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price